https://doi.org/10.55788/e829decf
In the phase 3 SENSCIS trial (NCT02597933), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). “The SENSCIS trial reflected a real-world population and allowed broad inclusion criteria,” Prof. Christopher Denton (University College London, United Kingdom) explained [1,2]. “Our analysis aimed to assess the effect of nintedanib on the rate of FVC decline but focusing on participants with risk factors for rapid FVC decline,” he said. The rate of decline in FVC over 52 weeks was analysed in participants with the following risk factors at baseline: early SSc (<18 months since the onset of first non-Raynaud symptom), elevated inflammatory markers (CRP ≥6 mg/L and/or platelets ≥330 x 109/L), and significant skin fibrosis using 2 approaches: modified Rodnan skin score (mRSS) 15–40 or mRSS ≥ 18.
Compared with the total population of the SENSCIS trial, participants with 1 of these risk factors at baseline had a greater decline in lung function. “Conversely, once these patients are on nintedanib, there is a stabilisation,” Prof. Denton said. These results support the prompt initiation of nintedanib in patients with SSc-ILD to preserve lung function and improve patient outcomes.
“I think this is an important analysis in terms of our clinical practice and perhaps future trial designs. It does support using nintedanib in this group of patients that might be at particular risk for lung function decline,” Prof. Denton concluded.
- Denton CP, et al. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial. OP0157, EULAR 2022 Congress, 1–4 June, Copenhagen, Denmark.
- Distler O, et al. N Engl J Med. 2019;380:2518–2528.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« New treatments in osteoarthritis Next Article
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement »
« New treatments in osteoarthritis Next Article
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement »
Table of Contents: EULAR 2022
Featured articles
Late-Breaking Oral Abstracts
TYK2 inhibition: the future of treating lupus erythematosus?
Psoriatic arthritis: significant improvement with bimekizumab
Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares
Spotlight on Rheumatoid Arthritis
Comorbid depression comes with a profoundly higher mortality risk in RA
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia
Risk factors for dementia in RA patients discovered
VTE in global registry data more common in JAK inhibitor-treated RA patients
Spondyloarthropathies – Novel Developments
How to treat enthesitis in 2022
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib
Treat-to-target dose reduction effective in spondyloarthritis
A novel oral treatment possibility for non-radiographic axSpA on the horizon
Many RA and PsA patients have problems with their sex life
What Is Hot in Osteoarthritis?
New treatments in osteoarthritis
OA associated with alcohol and drug abuse
Body mass index increase associated with structural changes in knee OA
What Is New in Lupus and Scleroderma
Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?
Pregnancies in SLE: many complications for mothers and their unborn children
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement
Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors
Best of the Posters
Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease
High prevalence of fibromyalgia in patients with inflammatory bowel disease
Related Articles
November 2, 2020
Post-colonoscopy colorectal cancers in IBD patients
January 26, 2021
COVID-19 vaccine recommended for all patients with IBD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com